查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553708

美國霧化器市場規模、佔有率、趨勢分析報告：按類型、按應用、按最終用途、細分市場預測，2024-2030 年

U.S. Nebulizer Market Size, Share & Trends Analysis Report By Type (Jet, Mesh, Ultrasonic), By Application (COPD, Asthma), By End-use (Hospitals & Clinics, Emergency Centers), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 70 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

美國霧化器市場成長與趨勢

Grand View Research, Inc.最新報告顯示，到2030年，美國霧化器市場規模預計將達到4.126億美元，預測期內複合年成長率為5.4%。

美國慢性呼吸道疾病盛行率上升、對居家醫療設備的需求增加以及老年人口的增加是推動市場成長的關鍵因素。

慢性呼吸道疾病盛行率上升是市場成長的關鍵驅動力。根據美國疾病管制與預防中心（CDC）發布的統計數據，美國約有1,840萬成年人美國氣喘。據 CDC 稱，2014 年，慢性阻塞性肺病(COPD) 估計是美國第三大死亡原因，當年約有 1570 萬美國被診斷出患有該疾病。過量攝取菸酒、不健康飲食、缺乏運動和驚人的肥胖率等因素也可能導致美國呼吸道疾病發病率上升，並促進霧化器市場在預測期內的成長。

近年來，居家醫療設備受到歡迎，市場佔有率不斷擴大。美國老年人口的不斷增加、目標疾病的高發病率以及控制醫療費用的需求不斷成長，預計將成為推動居家醫療器材普及的因素。居家醫療是替代昂貴住院治療的一種經濟有效的選擇。適合家庭使用的緊湊型霧化器現已上市，霧化器技術的創新降低了噪音並增加了功能，從而在居家醫療中得到越來越多的採用。此外，保險公司等第三方付款人也支援此類設備，因為他們的目標是在提供優質醫療服務的同時降低成本。預計這些因素也將有助於市場成長。

美國霧化器市場報告亮點

  • 與常規霧化器相比，Mesh 是一種先進技術，可提供快速、高效的藥物輸送，因此預計在預測期內的複合年成長率將達到 5.8%。
  • 2023年，氣喘細分市場佔據主導地位，佔據40.0%的市場佔有率。氣喘發生率很高，需要定期有效地服用藥物來控制疾病。
  • 2023年，醫院和診所市場將主導市場。醫院和診所描述了受控環境，醫生經過培訓可以透過霧化器給藥，特別是對於重症患者或需要加護治療的患者。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章美國霧化器市場變數、趨勢、範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國霧化器市場分析工具
    • 波特的分析
    • PESTEL分析

第4章美國霧化器市場：按類型、估計和趨勢分析

  • 細分儀表板
  • 美國霧化器市場：類型變化分析，2023 年和 2030 年
  • 噴射
  • 網
  • 超音波

第5章美國霧化器市場：按應用、估計和趨勢分析

  • 細分儀表板
  • 美國霧化器市場：2023 年和 2030 年應用變化分析
  • 慢性阻塞性肺病
  • 氣喘
  • 其他

第6章美國霧化器市場：依最終用途、估計和趨勢分析

  • 細分儀表板
  • 美國霧化器市場：2023 年和 2030 年最終用途變化分析
  • 醫院和診所
  • 急診中心
  • 其他

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • OMRON Healthcare, Inc.
    • GE Healthcare
    • Koninklijke Philips NV
    • Allied Healthcare
    • Vectura Group Plc.
    • PARI Respiratory Equipment, Inc.
    • Aerogen
    • DeVilbiss Healthcare LLC
    • Briggs Healthcare
    • Beurer GmBH
簡介目錄
Product Code: GVR-2-68038-085-9

U.S. Nebulizer Market Growth & Trends:

The U.S. nebulizer market size is anticipated to reach USD 412.6 million by 2030, according to a new report by Grand View Research, Inc., expanding at a 5.4% CAGR during the forecast period. Rising incidence of chronic respiratory diseases in U.S., increasing demand for home healthcare devices, and growing geriatric population are among the key factors driving market growth.

Rising incidence of chronic respiratory diseases is a crucial driver for market growth. According to statistics published by the Centers for Disease Control and Prevention (CDC), approximately 18.4 million adults in U.S. suffer from asthma. Chronic obstructive pulmonary disease (COPD) was estimated to be the third leading cause of death in the country in 2014, according to the CDC, with around 15.7 million Americans diagnosed with the condition that year. Factors such as overconsumption of tobacco and alcohol, unhealthy diet, lack of physical activity, and alarming rates of obesity are also likely to lead to an increase in incidence of respiratory disorders in U.S., contributing to the growth of the nebulizer market over the forecast period.

Home healthcare devices have been gaining popularity and market share in recent years. Growing geriatric population in U.S., high incidence of target diseases, and rising need to curb healthcare expenditure are expected to be some of the high-impact rendering drivers for home healthcare devices. Home healthcare is a cost-effective alternative to expensive hospital stays. Easy availability of compact nebulizers ideal for home use and technological innovations in nebulizers to reduce noise and improve functionality are increasing their adoption in home healthcare. Moreover, third-party payers, such as insurance companies, favor such devices as they aim to reduce costs while providing quality healthcare services. Such factors are also expected to contribute to market growth.

U.S. Nebulizer Market Report Highlights:

  • Mesh is expected to register the fastest CAGR of 5.8% over the forecast period owing to its advanced technology that provides fast and highly effective drug delivery when compared to that of a usual nebulizer.
  • The asthma segment dominated the market in 2023 and accounted for a market share of 40.0% driven by the high prevalence of asthma, which requires regular and effective administration of drugs for disease management.
  • The hospitals and clinics segment dominated the market in 2023. The hospitals and clinics provide a controlled environment with physicians trained to administer nebulized drugs, especially for critical cases or patients who require intensive care.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Nebulizer Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. U.S. Nebulizer Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. U.S. Nebulizer Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Nebulizer Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Jet
    • 4.3.1. Jet Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Mesh
    • 4.4.1. Mesh Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Ultrasonic
    • 4.5.1. Ultrasonic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Nebulizer Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Nebulizer Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. COPD
    • 5.3.1. COPD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Asthma
    • 5.4.1. Asthma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Nebulizer Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Nebulizer Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospitals and Clinics
    • 6.3.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Emergency Centers
    • 6.4.1. Emergency Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. OMRON Healthcare, Inc.
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. GE Healthcare
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. Koninklijke Philips N.V.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. Allied Healthcare
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. Vectura Group Plc.
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. PARI Respiratory Equipment, Inc.
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Aerogen
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. DeVilbiss Healthcare LLC
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives
    • 7.4.9. Briggs Healthcare
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/ Strategic Initiatives
    • 7.4.10. Beurer GmBH
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/ Strategic Initiatives